NCT00999505

Brief Summary

Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for phase_3 schizophrenia

Timeline
Completed

Started May 2010

Shorter than P25 for phase_3 schizophrenia

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 21, 2009

Completed
6 months until next milestone

Study Start

First participant enrolled

May 1, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
Last Updated

February 16, 2011

Status Verified

February 1, 2011

Enrollment Period

1.3 years

First QC Date

October 20, 2009

Last Update Submit

February 15, 2011

Conditions

Keywords

SchizophreniaAmantadineResidual symptoms

Outcome Measures

Primary Outcomes (1)

  • Scores in Brief Psychiatric Rating Scale

    Baseline, 4 weeks, 8 weeks, 12 weeks

Study Arms (2)

Amantadine

ACTIVE COMPARATOR

Amantadine 200mg twice a day

Drug: Amantadine

Placebo

PLACEBO COMPARATOR

Placebo capsules twice a day

Drug: Placebo

Interventions

Amantadine 200mg twice a day over 12 weeks

Also known as: Mantidan TM
Amantadine

Placebo capsules twice a day over 12 weeks

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Under antipsychotics with residual symptoms

You may not qualify if:

  • Pregnancy
  • Lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

RECRUITING

MeSH Terms

Conditions

Schizophrenia

Interventions

Amantadine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

AdamantaneBridged-Ring CompoundsHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Clarissa S Gama, MD, PhD

    Hospital de Clinicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clarissa S Gama, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 20, 2009

First Posted

October 21, 2009

Study Start

May 1, 2010

Primary Completion

September 1, 2011

Study Completion

September 1, 2011

Last Updated

February 16, 2011

Record last verified: 2011-02

Locations